Several studies have attempted to relate BAG-1 protein expression to disease outcome with inconsistent results, which may have been the result of low patient numbers, low rates of ER+ tumours (ER+ rates of 35–52% rather than a currently expected rate of ∼70%) and incomplete pathological, clinical and treatment information. The gene discussed is BAG1; the disease is neoplasm.